Burning Rock Q2 FY26 net loss widens to RMB 18.4 million; revenue drops 9.3% to RMB 134.7 million

• Burning Rock posted Q2 2026 revenue of RMB 134.7 million, down 9.3% from a year earlier.
• Net loss widened to RMB 18.4 million from RMB 9.7 million.
• Gross margin edged down 0.2 percentage points to 72.6%; operating expenses fell 3.2% to RMB 115.8 million on cost controls.
• In-hospital revenue rose 7.4% to RMB 67.1 million, while central laboratory revenue fell 10% to RMB 36.8 million on fewer tests.
• OncoScreen BCMatch Tissue Kit entered NMPA priority review; CanCatch Custom Kit entered NMPA innovative device review; OncoCompass liquid kit priority review was resubmitted, accepted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-387190), on September 10, 2026, and is solely responsible for the information contained therein.